|
JP2988739B2
(ja)
*
|
1990-04-16 |
1999-12-13 |
協和醗酵工業株式会社 |
１，８−ナフチリジン−２−オン誘導体
|
|
DE4227747A1
(de)
|
1992-08-21 |
1994-02-24 |
Basf Ag |
Heteroaromatisch kondensierte Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
|
|
KR100828982B1
(ko)
*
|
2000-12-28 |
2008-05-14 |
시오노기세이야쿠가부시키가이샤 |
칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
EP1467970B1
(en)
*
|
2002-01-17 |
2007-08-22 |
Merck & Co., Inc. |
Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
CN1875021A
(zh)
|
2003-11-04 |
2006-12-06 |
默克公司 |
取代的萘啶酮衍生物
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
AR059733A1
(es)
|
2006-03-07 |
2008-04-23 |
Smithkline Beecham Corp |
Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
|
|
ES2393326T3
(es)
|
2006-12-18 |
2012-12-20 |
Amgen, Inc |
Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
|
|
US8048894B2
(en)
|
2007-04-18 |
2011-11-01 |
Amgen Inc. |
Quinolones and azaquinolones that inhibit prolyl hydroxylase
|
|
BR122017025062B8
(pt)
|
2007-06-18 |
2021-07-27 |
Merck Sharp & Dohme |
anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
|
|
WO2009053799A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Glenmark Pharmaceuticals, S.A. |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
|
GB0800855D0
(en)
|
2008-01-17 |
2008-02-27 |
Syngenta Ltd |
Herbicidal compounds
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
EP2482849B1
(en)
|
2009-09-30 |
2018-06-06 |
Memorial Sloan-Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
|
KR20130020881A
(ko)
*
|
2010-02-08 |
2013-03-04 |
알러간, 인코포레이티드 |
칸나비노이드-2 효능제로서 유용한 피리다진 유도체
|
|
WO2013165898A2
(en)
|
2012-05-01 |
2013-11-07 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for inhibiting resolvases
|
|
SMT202100065T1
(it)
|
2013-05-02 |
2021-03-15 |
Anaptysbio Inc |
Anticorpi diretti contro la proteina della morte programmata (pd-1)
|
|
WO2016039749A1
(en)
|
2014-09-11 |
2016-03-17 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
|
|
JP6777638B2
(ja)
|
2014-09-19 |
2020-10-28 |
マッカイ メディカル ファンデーション ザ プレスビュテロス チャーチ イン タイワン マッカイ メモリアル ホスピタル |
ベンゾ複素環化合物および薬剤
|
|
US20180044350A1
(en)
|
2015-03-10 |
2018-02-15 |
Pottayil Govindan Nair Sasikumar |
Therapeutic cyclic compounds as immunomodulators
|
|
BR112017019304A2
(pt)
|
2015-03-10 |
2018-05-08 |
Aurigene Discovery Technologies Limited |
compostos de 1,2,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
|
|
BR112017019307A2
(pt)
|
2015-03-10 |
2018-05-02 |
Aurigene Discovery Technologies Limited |
compostos de 1,3,4-oxadiazol 3-substituído e tiadiazol como imunomoduladores
|
|
KR102894264B1
(ko)
|
2015-03-10 |
2025-12-02 |
오리진 온콜로지 리미티드 |
면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
|
|
EA201791629A1
(ru)
|
2015-03-10 |
2018-02-28 |
Ауриджен Дискавери Текнолоджис Лимитед |
1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
|
|
US10745382B2
(en)
|
2015-10-15 |
2020-08-18 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
WO2017070089A1
(en)
|
2015-10-19 |
2017-04-27 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
WO2017068349A1
(en)
*
|
2015-10-23 |
2017-04-27 |
E-Therapeutics Plc |
Cannabinoid for use in immunotherapy
|
|
WO2017079669A1
(en)
|
2015-11-04 |
2017-05-11 |
Incyte Corporation |
Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor
|
|
SG10202004618TA
(en)
|
2015-11-19 |
2020-06-29 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
|
MA44075A
(fr)
|
2015-12-17 |
2021-05-19 |
Incyte Corp |
Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
|
|
AU2016379372A1
(en)
|
2015-12-22 |
2018-08-02 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
EP3190103A1
(en)
|
2016-01-08 |
2017-07-12 |
Rijksuniversiteit Groningen |
Inhibitors of the pd-1/pd-l1 protein/protein interaction
|
|
US9798514B2
(en)
|
2016-03-09 |
2017-10-24 |
Spotify Ab |
System and method for color beat display in a media content environment
|
|
US20190062272A1
(en)
|
2016-04-13 |
2019-02-28 |
Capten Therapeutics Inc. |
Small molecules for immunogenic treatment of cancer
|
|
AR108396A1
(es)
|
2016-05-06 |
2018-08-15 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
|
WO2017202275A1
(zh)
|
2016-05-23 |
2017-11-30 |
中国医学科学院药物研究所 |
溴代苄醚衍生物、及其制法和药物组合物与用途
|
|
CA3025391A1
(en)
|
2016-05-26 |
2017-11-30 |
Merck Patent Gmbh |
Pd-1 / pd-l1 inhibitors for cancer treatment
|
|
WO2017205464A1
(en)
|
2016-05-26 |
2017-11-30 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
HUE060256T2
(hu)
|
2016-06-20 |
2023-02-28 |
Incyte Corp |
Heterociklusos vegyületek mint immunmodulátorok
|
|
EA201990221A1
(ru)
|
2016-07-08 |
2019-06-28 |
Бристол-Маерс Сквибб Компани |
1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
|
|
JP2019530732A
(ja)
|
2016-08-03 |
2019-10-24 |
アライジング・インターナショナル・インコーポレイテッドＡｒｉｓｉｎｇ Ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｉｎｃ． |
免疫モジュレータとして有用な対称または半対称化合物
|
|
US10563620B2
(en)
|
2016-08-12 |
2020-02-18 |
Rolls-Royce North American Technologies Inc. |
Expandable exhaust cone
|
|
WO2018044783A1
(en)
|
2016-08-29 |
2018-03-08 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
|
US10734026B2
(en)
|
2016-09-01 |
2020-08-04 |
Facebook, Inc. |
Systems and methods for dynamically providing video content based on declarative instructions
|
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
CA3070073A1
(en)
|
2017-07-18 |
2019-01-24 |
Nuvation Bio Inc. |
1,8-naphthyridinone compounds and uses thereof
|
|
CR20200347A
(es)
|
2018-02-13 |
2020-09-23 |
Gilead Sciences Inc |
Inhibidores pd-1/pd-l1
|
|
TWI712412B
(zh)
|
2018-04-19 |
2020-12-11 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
|
SG11202012425QA
(en)
|
2018-07-13 |
2021-01-28 |
Gilead Sciences Inc |
Pd-1/pd-l1 inhibitors
|
|
WO2020086556A1
(en)
|
2018-10-24 |
2020-04-30 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
KR20230041654A
(ko)
*
|
2020-05-05 |
2023-03-24 |
테온 테라퓨틱스, 인크. |
칸나비노이드 수용체 유형 2 (cb2) 조정제 및 그의 용도
|